Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1CNS 1

Conditions

Prostatic Neoplasms 1Glioblastoma 1Adenocarcinoma 1

Interventions

pembrolizumab 282Carboplatin 217Cisplatin 147Gemcitabine 146Paclitaxel 142Bevacizumab 116Pemetrexed 114Docetaxel 101Oxaliplatin 79durvalumab 78Dexamethasone 77Fluorouracil 76atezolizumab 75Nivolumab 75Cyclophosphamide 74130-nm albumin-bound paclitaxel 71Fulvestrant 70Capecitabine 64Cetuximab 63Injections 62Leucovorin 60Rituximab 55fludarabine 50Lenalidomide 50venetoclax 44Prednisone 43Irinotecan 42Letrozole 40enzalutamide 39tislelizumab 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Valacyclovir × 90 days × Clear all
NCT07346144 2026-05-04

ADePT

Trogenix ltd

Phase 1/2 Recruiting
68 enrolled
CNS

Glioblastoma

NCT07332000 2026-03-20

A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec

Candel Therapeutics, Inc.

Phase 2 Recruiting
45 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡